,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvY2AR'}, 'Id': 'a0POZ00000B4bvY2AR', 'Event_Date__c': '2018-02-15', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArQ4QAK'}, 'change': None}]",Feb 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2018', 'fs': 'Jun 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvZ2AR'}, 'Id': 'a0POZ00000B4bvZ2AR', 'Event_Date__c': '2018-06-13', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2018', 'Status_History__c': 'a132P000000ArTsQAK'}, 'change': None}, {'Summary': {'s': 'PTAC recommended the application be referred to the Cancer Treatment Subcommittee of PTAC (CaTSoP) for advice regarding the potential health benefits of obinutuzumab for the first-line induction and maintenance treatment of follicular lymphoma.', 'fs': 'PTAC recommended the application be referred to the Cancer Treatment Subcommittee of PTAC (CaTSoP) for advice regarding the potential health benefits of obinutuzumab for the first-line induction and maintenance treatment of follicular lymphoma.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2018', 'fs': 'Aug 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bva2AB'}, 'Id': 'a0POZ00000B4bva2AB', 'Event_Date__c': '2018-08-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'PTAC recommended the application be referred to the Cancer Treatment Subcommittee of PTAC (CaTSoP) for advice regarding the potential health benefits of obinutuzumab for the first-line induction and maintenance treatment of follicular lymphoma.', 'Formatted_Date__c': 'Aug 2018', 'Status_History__c': 'a132P000000ArVBQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2019', 'fs': 'Jan 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvb2AB'}, 'Id': 'a0POZ00000B4bvb2AB', 'Event_Date__c': '2019-01-24', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jan 2019', 'Status_History__c': 'a132P000000AraQQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, be funded with a medium priority. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation due to the unmet need of this small patient group, the highly relevant clinical trial evidence (to New Zealand patients) and the evidence for a difference in PFS, a clear difference in OS (despite immature data) and reasonable toxicity profile associated with obinutuzumab.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following new Special Authority criteria for obinutuzumab for the treatment of the above recommended patient group: </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Special Authority for Subsidy</span><span style=""font-size: 9pt; color: black;""> - PCT only – Specialist</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an indolent low grade lymphoma; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is refractory to any previous regimen containing rituximab; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance status of 0-2; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has been previously treated with no more than four chemotherapy regimens; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum dose of 1000 mg in combination with bendamustine at a maximum dose of 90 mg/m2 for a maximum of 6 cycles; and</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Renewal application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has no evidence of disease progression following obinutuzumab induction therapy; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be discontinued at disease progression.</span></p><p><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Note: &#39;Indolent, low-grade lymphomas&#39; includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab-refractory is defined as failure to respond to, or progression during, any previous rituximab-containing regimen (monotherapy or combined with chemotherapy), or progression within 6 months of the last rituximab dose, in the induction or maintenance treatment settings. Response to first-line systemic chemotherapy in combination with obinutuzumab needs to be assessed 2-4 weeks after the last treatment course. Maintenance therapy should commence at 8 weeks after completion of the first-line systemic treatment.</span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following change to the Special Authority criteria for bendamustine in both initial and renewal (additional text in <b>bold</b>): </p><p style=""text-align: justify;""><i style=""color: black; font-size: 10pt;"">Bendamustine is to be administered as a monotherapy </i><b style=""color: black; font-size: 10pt;""><i>or in combination with obinutuzumab</i></b><i style=""color: black; font-size: 10pt;""> for a maximum of 6 cycles in rituximab refractory patients</i></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL) be deferred. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee decided that in order to consider this application sufficiently it would need to see mature PFS and safety data for this patient group from the GALLIUM trial (unlikely to be available for at least a few years), and considered OS data was unlikely to be forthcoming in this patient group.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, be funded with a medium priority. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation due to the unmet need of this small patient group, the highly relevant clinical trial evidence (to New Zealand patients) and the evidence for a difference in PFS, a clear difference in OS (despite immature data) and reasonable toxicity profile associated with obinutuzumab.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following new Special Authority criteria for obinutuzumab for the treatment of the above recommended patient group: </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Special Authority for Subsidy</span><span style=""font-size: 9pt; color: black;""> - PCT only – Specialist</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an indolent low grade lymphoma; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is refractory to any previous regimen containing rituximab; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance status of 0-2; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has been previously treated with no more than four chemotherapy regimens; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum dose of 1000 mg in combination with bendamustine at a maximum dose of 90 mg/m2 for a maximum of 6 cycles; and</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Renewal application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has no evidence of disease progression following obinutuzumab induction therapy; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be discontinued at disease progression.</span></p><p><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Note: &#39;Indolent, low-grade lymphomas&#39; includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab-refractory is defined as failure to respond to, or progression during, any previous rituximab-containing regimen (monotherapy or combined with chemotherapy), or progression within 6 months of the last rituximab dose, in the induction or maintenance treatment settings. Response to first-line systemic chemotherapy in combination with obinutuzumab needs to be assessed 2-4 weeks after the last treatment course. Maintenance therapy should commence at 8 weeks after completion of the first-line systemic treatment.</span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following change to the Special Authority criteria for bendamustine in both initial and renewal (additional text in <b>bold</b>): </p><p style=""text-align: justify;""><i style=""color: black; font-size: 10pt;"">Bendamustine is to be administered as a monotherapy </i><b style=""color: black; font-size: 10pt;""><i>or in combination with obinutuzumab</i></b><i style=""color: black; font-size: 10pt;""> for a maximum of 6 cycles in rituximab refractory patients</i></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL) be deferred. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee decided that in order to consider this application sufficiently it would need to see mature PFS and safety data for this patient group from the GALLIUM trial (unlikely to be available for at least a few years), and considered OS data was unlikely to be forthcoming in this patient group.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>General discussion</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that treatment of indolent non-Hodgkin lymphoma (NHL), including follicular lymphoma (FL), in New Zealand consists of multiple treatment lines using rituximab in combination with chemotherapy (predominantly bendamustine-rituximab for first line therapy), with stem cell transplant in appropriate cases at later relapse. The Subcommittee noted that funding restrictions for rituximab or bendamustine retreatment require rituximab- or bendamustine-treatment free intervals of 12-months. The Subcommittee noted that approximately 14% of patients with NHL will experience rituximab-refractory disease or relapse within six months of rituximab treatment. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that rituximab maintenance therapy for FL is not currently funded in New Zealand, but that an application for rituximab maintenance therapy for CD20+ low-grade or follicular B-cell NHL received a medium priority recommendation from CaTSoP in April 2018. The Subcommittee considered that funded rituximab maintenance would not change the health need of patients who ultimately become rituximab-refractory.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that treatment of indolent non-Hodgkin lymphoma in the third line and later is challenging, especially for rapidly relapsing disease, that most patients with NHL eventually relapse, and that antibody treatments (eg rituximab) offer more benefit if used in combination with chemotherapy.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab, like rituximab, is an anti-CD20 monoclonal antibody but that obinutuzumab has a broader mechanism of action and uses a direct pathway to cause malignant cell death. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab is Medsafe-approved for first-line treatment of patients with FL (in combination with chemotherapy followed by maintenance) and for patients with indolent NHL who did not respond to, or who progressed during/within 6 months of prior rituximab (in combination with bendamustine followed by maintenance).</p><p>Obinutuzumab for relapsed/refractory indolent NHL </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for indolent NHL was reviewed by PTAC, which recommended funding with a low priority, and noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS, uncertain evidence of an OS benefit, and no significant difference in safety or HRQoL. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the need for another agent in NHL and the potential impact of increasing infusion requirements due to maintenance therapy.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the applicant’s patient number estimate (N = 36) was reasonable and the estimate by PHARMAC staff (N = 9, based on bendamustine use in rituximab-refractory patients) was too low, but that bendamustine may be contraindicated in patients who are heavily pre-treated, of advanced age, or have co-morbidities. The Subcommittee considered that the small group of patients with relapsed/refractory indolent NHL have an unmet health need and that uptake of obinutuzumab plus bendamustine could be low due to patient characteristics. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab in combination with bendamustine for rituximab-refractory indolent NHL comes from the phase 3 GADOLIN trial; an open-label, randomised (1:1), multicentre trial that investigated the efficacy and safety of induction therapy with obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy, compared with bendamustine monotherapy induction therapy, in 413 patients with rituximab-refractory indolent NHL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27345636"" target=""_blank"">(Sehn et al. Lancet Oncol. 2016;17:1081-93; Cheson et al. J Clin Oncol. 2018;36:2259-66).</a> </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that limitations of the GADOLIN trial design and patient group characteristics would have biased the results; specifically, different doses of bendamustine (120 mg as monotherapy; 90 mg with obinutuzumab), use of bendamustine monotherapy as a comparator and without maintenance (patients more likely to progress than with obinutuzumab plus bendamustine), imbalances in the proportion of patients refractory to prior rituximab monotherapy (18.6% in the obinutuzumab plus bendamustine group and 23.0% in the monotherapy group in the intention-to-treat population, and in 15.2% and 24.6%, respectively, of patients with FL), and broad definitions of rituximab-refractory (applying to prior rituximab monotherapy and rituximab-containing combination chemotherapy regimens). The Subcommittee considered that rituximab monotherapy is seldom used in New Zealand, as patients may respond to rituximab with chemotherapy. </p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the UK National Institute for Health and Care Excellence (NICE) technology appraisal of obinutuzumab plus bendamustine had reported limitations in estimates of overall survival (OS) which favoured the intervention <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29594951"" target=""_blank"">(Rafia et al. Pharmacoeconomics. 2018;36:1143-51)</a>.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the median progression-free survival (PFS) in the GADOLIN trial was 25.8 months with obinutuzumab plus bendamustine compared to 14.1 months with bendamustine monotherapy (HR 0.57; 95% CI 0.44 to 0.73; P&lt;0.001). The Subcommittee noted that median OS was not reached for either group, where the Kaplan Meir survival differences were statistically significant (HR 0.67; 95% CI 0.47-0.96; P=0.0269) and considered that a reasonable number of survival events had occurred. The Subcommittee noted that the PFS and OS results were consistent in the FL patient subgroups <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29584548"" target=""_blank"">(Cheson et al. J Clin Oncol. 2018;36:2259-66)</a>.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that obinutuzumab had a reasonable safety profile, that adverse events (AEs) were similar between the treatment groups, and that the higher proportion of treatment withdrawals due to AEs with bendamustine monotherapy may be due to poor tolerance of the larger bendamustine dose in this group.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that GADOLIN demonstrated a PFS benefit and an apparent OS effect, despite the published data not being fully mature and the limitations of the trial. </p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the clinical trial evidence from the GADOLIN trial was highly relevant to New Zealand patients with indolent NHL, because the trial control arm used bendamustine monotherapy as would be the case in New Zealand for rituximab-refractory patients where a rituximab treatment-free interval of 12 months or more is required for renewal of rituximab on relapse. </p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the infusion resource required to administer obinutuzumab maintenance every 2 months for 2 years or until disease progression was small, that a small number of patients would receive this treatment, and that obinutuzumab maintenance would require similar infusion resources to maintenance rituximab (if funded), however, obinutuzumab may be more challenging to administer than rituximab. The Subcommittee considered that uptake of this regimen might be quite low. </p><p>Obinutuzumab for first-line treatment of FL</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for FL was reviewed by PTAC, which recommended the application be deferred pending further data, and that PTAC considered it should be funded only if cost-neutral to rituximab maintenance. The Subcommittee noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS but no evidence of quality of life benefit and no clear evidence of OS benefit with obinutuzumab compared with rituximab. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the long-term safety data of obinutuzumab and the likely efficacy of retreatment with obinutuzumab or rituximab.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the patient number estimates by the applicant (N = 119) and PHARMAC staff (N = 88) were reasonable estimates of the number of newly diagnosed patients with FL, although they could be slightly overestimated.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab induction and maintenance therapy for the first-line treatment of FL derives from the GALLIUM trial; an open-label, phase 3, randomised (1:1) trial that investigated the efficacy and safety of obinutuzumab plus chemotherapy induction therapy compared with rituximab plus chemotherapy followed by maintenance with the same antibody in 1202 patients with previously untreated FL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28976863"" target=""_blank"">(Marcus et al. N Engl J Med. 2017;377:1331-44</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the GALLIUM trial was of good quality, where it included patients with up to grade 3a disease, used the GELF tumour burden criteria for treatment eligibility, had a standard rituximab treatment schedule, and had a good balance of patients between treatment groups. The Subcommittee noted that three chemotherapy regimens were allowed: bendamustine (used in 57.1% of patients), CHOP (33.1%) and CVP (9.8%).</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that after a median follow-up of 41 months, the 3-year investigator-assessed PFS rate in the GALLIUM trial was 82% in the obinutuzumab group compared with 75% in the rituximab group (HR 0.68; 95% CI 0.54 to 0.87; P=0.0016), and that results of PFS as assessed by independent review committee were similar. Members considered that the PFS results by chemotherapy regimen were consistent. The Subcommittee noted that the 3-year OS rate was 94% in the obinutuzumab group compared with 92% in the rituximab group (HR 0.82; 95% CI 0.54 to 1.22; P=0.32) <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">(Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that secondary malignancy occurred in 5% of patients receiving bendamustine, more infections were reported in patients receiving bendamustine (20-26%) than other regimens (12-20%), and higher rates of grade 3-5 cytopenias were reported in patients receiving CHOP than with other regimens. The Subcommittee considered these safety signals were small, but that longer-term data is needed to evaluate their clinical significance. </p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in patients older than 70 years that a higher proportion of fatal events occurred prior to starting new anticancer therapy with bendamustine (13%) compared with CHOP (2%) or CVP (4%), and considered this was a concern due to patients likely being older at the time of their diagnosis with FL.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the difference in PFS between groups was small and that the GALLIUM trial data was too immature to conclude whether obinutuzumab would be preferred over rituximab for induction and maintenance treatment for FL. The Subcommittee requested that it see mature efficacy and safety data, once available, although it considered these data unlikely to be available for at least a few years. The Subcommittee considered that OS data was unlikely to be produced as it is challenging to obtain this in FL, due to confounding from crossovers with subsequent multiple lines of therapy.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there is no available data for retreatment using either obinutuzumab or rituximab after obinutuzumab in the first-line setting, and considered that the efficacy and safety of retreatment with obinutuzumab or rituximab is currently unknown. The Subcommittee considered that long-term safety and efficacy data are lacking in FL and there is a small signal for increased infections and secondary malignancy that requires additional follow up to determine if this is a concern.</p>', 'fs': '<p>General discussion</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that treatment of indolent non-Hodgkin lymphoma (NHL), including follicular lymphoma (FL), in New Zealand consists of multiple treatment lines using rituximab in combination with chemotherapy (predominantly bendamustine-rituximab for first line therapy), with stem cell transplant in appropriate cases at later relapse. The Subcommittee noted that funding restrictions for rituximab or bendamustine retreatment require rituximab- or bendamustine-treatment free intervals of 12-months. The Subcommittee noted that approximately 14% of patients with NHL will experience rituximab-refractory disease or relapse within six months of rituximab treatment. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that rituximab maintenance therapy for FL is not currently funded in New Zealand, but that an application for rituximab maintenance therapy for CD20+ low-grade or follicular B-cell NHL received a medium priority recommendation from CaTSoP in April 2018. The Subcommittee considered that funded rituximab maintenance would not change the health need of patients who ultimately become rituximab-refractory.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that treatment of indolent non-Hodgkin lymphoma in the third line and later is challenging, especially for rapidly relapsing disease, that most patients with NHL eventually relapse, and that antibody treatments (eg rituximab) offer more benefit if used in combination with chemotherapy.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab, like rituximab, is an anti-CD20 monoclonal antibody but that obinutuzumab has a broader mechanism of action and uses a direct pathway to cause malignant cell death. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab is Medsafe-approved for first-line treatment of patients with FL (in combination with chemotherapy followed by maintenance) and for patients with indolent NHL who did not respond to, or who progressed during/within 6 months of prior rituximab (in combination with bendamustine followed by maintenance).</p><p>Obinutuzumab for relapsed/refractory indolent NHL </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for indolent NHL was reviewed by PTAC, which recommended funding with a low priority, and noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS, uncertain evidence of an OS benefit, and no significant difference in safety or HRQoL. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the need for another agent in NHL and the potential impact of increasing infusion requirements due to maintenance therapy.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the applicant’s patient number estimate (N = 36) was reasonable and the estimate by PHARMAC staff (N = 9, based on bendamustine use in rituximab-refractory patients) was too low, but that bendamustine may be contraindicated in patients who are heavily pre-treated, of advanced age, or have co-morbidities. The Subcommittee considered that the small group of patients with relapsed/refractory indolent NHL have an unmet health need and that uptake of obinutuzumab plus bendamustine could be low due to patient characteristics. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab in combination with bendamustine for rituximab-refractory indolent NHL comes from the phase 3 GADOLIN trial; an open-label, randomised (1:1), multicentre trial that investigated the efficacy and safety of induction therapy with obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy, compared with bendamustine monotherapy induction therapy, in 413 patients with rituximab-refractory indolent NHL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27345636"" target=""_blank"">(Sehn et al. Lancet Oncol. 2016;17:1081-93; Cheson et al. J Clin Oncol. 2018;36:2259-66).</a> </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that limitations of the GADOLIN trial design and patient group characteristics would have biased the results; specifically, different doses of bendamustine (120 mg as monotherapy; 90 mg with obinutuzumab), use of bendamustine monotherapy as a comparator and without maintenance (patients more likely to progress than with obinutuzumab plus bendamustine), imbalances in the proportion of patients refractory to prior rituximab monotherapy (18.6% in the obinutuzumab plus bendamustine group and 23.0% in the monotherapy group in the intention-to-treat population, and in 15.2% and 24.6%, respectively, of patients with FL), and broad definitions of rituximab-refractory (applying to prior rituximab monotherapy and rituximab-containing combination chemotherapy regimens). The Subcommittee considered that rituximab monotherapy is seldom used in New Zealand, as patients may respond to rituximab with chemotherapy. </p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the UK National Institute for Health and Care Excellence (NICE) technology appraisal of obinutuzumab plus bendamustine had reported limitations in estimates of overall survival (OS) which favoured the intervention <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29594951"" target=""_blank"">(Rafia et al. Pharmacoeconomics. 2018;36:1143-51)</a>.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the median progression-free survival (PFS) in the GADOLIN trial was 25.8 months with obinutuzumab plus bendamustine compared to 14.1 months with bendamustine monotherapy (HR 0.57; 95% CI 0.44 to 0.73; P&lt;0.001). The Subcommittee noted that median OS was not reached for either group, where the Kaplan Meir survival differences were statistically significant (HR 0.67; 95% CI 0.47-0.96; P=0.0269) and considered that a reasonable number of survival events had occurred. The Subcommittee noted that the PFS and OS results were consistent in the FL patient subgroups <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29584548"" target=""_blank"">(Cheson et al. J Clin Oncol. 2018;36:2259-66)</a>.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that obinutuzumab had a reasonable safety profile, that adverse events (AEs) were similar between the treatment groups, and that the higher proportion of treatment withdrawals due to AEs with bendamustine monotherapy may be due to poor tolerance of the larger bendamustine dose in this group.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that GADOLIN demonstrated a PFS benefit and an apparent OS effect, despite the published data not being fully mature and the limitations of the trial. </p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the clinical trial evidence from the GADOLIN trial was highly relevant to New Zealand patients with indolent NHL, because the trial control arm used bendamustine monotherapy as would be the case in New Zealand for rituximab-refractory patients where a rituximab treatment-free interval of 12 months or more is required for renewal of rituximab on relapse. </p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the infusion resource required to administer obinutuzumab maintenance every 2 months for 2 years or until disease progression was small, that a small number of patients would receive this treatment, and that obinutuzumab maintenance would require similar infusion resources to maintenance rituximab (if funded), however, obinutuzumab may be more challenging to administer than rituximab. The Subcommittee considered that uptake of this regimen might be quite low. </p><p>Obinutuzumab for first-line treatment of FL</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for FL was reviewed by PTAC, which recommended the application be deferred pending further data, and that PTAC considered it should be funded only if cost-neutral to rituximab maintenance. The Subcommittee noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS but no evidence of quality of life benefit and no clear evidence of OS benefit with obinutuzumab compared with rituximab. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the long-term safety data of obinutuzumab and the likely efficacy of retreatment with obinutuzumab or rituximab.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the patient number estimates by the applicant (N = 119) and PHARMAC staff (N = 88) were reasonable estimates of the number of newly diagnosed patients with FL, although they could be slightly overestimated.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab induction and maintenance therapy for the first-line treatment of FL derives from the GALLIUM trial; an open-label, phase 3, randomised (1:1) trial that investigated the efficacy and safety of obinutuzumab plus chemotherapy induction therapy compared with rituximab plus chemotherapy followed by maintenance with the same antibody in 1202 patients with previously untreated FL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28976863"" target=""_blank"">(Marcus et al. N Engl J Med. 2017;377:1331-44</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the GALLIUM trial was of good quality, where it included patients with up to grade 3a disease, used the GELF tumour burden criteria for treatment eligibility, had a standard rituximab treatment schedule, and had a good balance of patients between treatment groups. The Subcommittee noted that three chemotherapy regimens were allowed: bendamustine (used in 57.1% of patients), CHOP (33.1%) and CVP (9.8%).</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that after a median follow-up of 41 months, the 3-year investigator-assessed PFS rate in the GALLIUM trial was 82% in the obinutuzumab group compared with 75% in the rituximab group (HR 0.68; 95% CI 0.54 to 0.87; P=0.0016), and that results of PFS as assessed by independent review committee were similar. Members considered that the PFS results by chemotherapy regimen were consistent. The Subcommittee noted that the 3-year OS rate was 94% in the obinutuzumab group compared with 92% in the rituximab group (HR 0.82; 95% CI 0.54 to 1.22; P=0.32) <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">(Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that secondary malignancy occurred in 5% of patients receiving bendamustine, more infections were reported in patients receiving bendamustine (20-26%) than other regimens (12-20%), and higher rates of grade 3-5 cytopenias were reported in patients receiving CHOP than with other regimens. The Subcommittee considered these safety signals were small, but that longer-term data is needed to evaluate their clinical significance. </p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in patients older than 70 years that a higher proportion of fatal events occurred prior to starting new anticancer therapy with bendamustine (13%) compared with CHOP (2%) or CVP (4%), and considered this was a concern due to patients likely being older at the time of their diagnosis with FL.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the difference in PFS between groups was small and that the GALLIUM trial data was too immature to conclude whether obinutuzumab would be preferred over rituximab for induction and maintenance treatment for FL. The Subcommittee requested that it see mature efficacy and safety data, once available, although it considered these data unlikely to be available for at least a few years. The Subcommittee considered that OS data was unlikely to be produced as it is challenging to obtain this in FL, due to confounding from crossovers with subsequent multiple lines of therapy.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there is no available data for retreatment using either obinutuzumab or rituximab after obinutuzumab in the first-line setting, and considered that the efficacy and safety of retreatment with obinutuzumab or rituximab is currently unknown. The Subcommittee considered that long-term safety and efficacy data are lacking in FL and there is a small signal for increased infections and secondary malignancy that requires additional follow up to determine if this is a concern.</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the following applications from Roche Products (New Zealand) Ltd:</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, and</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the following applications from Roche Products (New Zealand) Ltd:</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, and</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>PTAC <span style=""font-family: Arial, sans-serif; font-size: 10pt;"">noted and agreed with the Subcommittee’s recorded considerations and recommendations regarding the record. </span></p>', 'fs': '<p>PTAC <span style=""font-family: Arial, sans-serif; font-size: 10pt;"">noted and agreed with the Subcommittee’s recorded considerations and recommendations regarding the record. </span></p>', 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvc2AB'}, 'Id': 'a0POZ00000B4bvc2AB', 'Event_Date__c': '2019-10-18', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'Oct 2019', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, be funded with a medium priority. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation due to the unmet need of this small patient group, the highly relevant clinical trial evidence (to New Zealand patients) and the evidence for a difference in PFS, a clear difference in OS (despite immature data) and reasonable toxicity profile associated with obinutuzumab.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following new Special Authority criteria for obinutuzumab for the treatment of the above recommended patient group: </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Special Authority for Subsidy</span><span style=""font-size: 9pt; color: black;""> - PCT only – Specialist</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an indolent low grade lymphoma; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is refractory to any previous regimen containing rituximab; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance status of 0-2; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has been previously treated with no more than four chemotherapy regimens; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum dose of 1000 mg in combination with bendamustine at a maximum dose of 90 mg/m2 for a maximum of 6 cycles; and</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Renewal application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has no evidence of disease progression following obinutuzumab induction therapy; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be discontinued at disease progression.</span></p><p><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Note: &#39;Indolent, low-grade lymphomas&#39; includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab-refractory is defined as failure to respond to, or progression during, any previous rituximab-containing regimen (monotherapy or combined with chemotherapy), or progression within 6 months of the last rituximab dose, in the induction or maintenance treatment settings. Response to first-line systemic chemotherapy in combination with obinutuzumab needs to be assessed 2-4 weeks after the last treatment course. Maintenance therapy should commence at 8 weeks after completion of the first-line systemic treatment.</span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following change to the Special Authority criteria for bendamustine in both initial and renewal (additional text in <b>bold</b>): </p><p style=""text-align: justify;""><i style=""color: black; font-size: 10pt;"">Bendamustine is to be administered as a monotherapy </i><b style=""color: black; font-size: 10pt;""><i>or in combination with obinutuzumab</i></b><i style=""color: black; font-size: 10pt;""> for a maximum of 6 cycles in rituximab refractory patients</i></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL) be deferred. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee decided that in order to consider this application sufficiently it would need to see mature PFS and safety data for this patient group from the GALLIUM trial (unlikely to be available for at least a few years), and considered OS data was unlikely to be forthcoming in this patient group.\xa0</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the following applications from Roche Products (New Zealand) Ltd:</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, and</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>General discussion</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that treatment of indolent non-Hodgkin lymphoma (NHL), including follicular lymphoma (FL), in New Zealand consists of multiple treatment lines using rituximab in combination with chemotherapy (predominantly bendamustine-rituximab for first line therapy), with stem cell transplant in appropriate cases at later relapse. The Subcommittee noted that funding restrictions for rituximab or bendamustine retreatment require rituximab- or bendamustine-treatment free intervals of 12-months. The Subcommittee noted that approximately 14% of patients with NHL will experience rituximab-refractory disease or relapse within six months of rituximab treatment. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that rituximab maintenance therapy for FL is not currently funded in New Zealand, but that an application for rituximab maintenance therapy for CD20+ low-grade or follicular B-cell NHL received a medium priority recommendation from CaTSoP in April 2018. The Subcommittee considered that funded rituximab maintenance would not change the health need of patients who ultimately become rituximab-refractory.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that treatment of indolent non-Hodgkin lymphoma in the third line and later is challenging, especially for rapidly relapsing disease, that most patients with NHL eventually relapse, and that antibody treatments (eg rituximab) offer more benefit if used in combination with chemotherapy.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab, like rituximab, is an anti-CD20 monoclonal antibody but that obinutuzumab has a broader mechanism of action and uses a direct pathway to cause malignant cell death. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab is Medsafe-approved for first-line treatment of patients with FL (in combination with chemotherapy followed by maintenance) and for patients with indolent NHL who did not respond to, or who progressed during/within 6 months of prior rituximab (in combination with bendamustine followed by maintenance).</p><p>Obinutuzumab for relapsed/refractory indolent NHL </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for indolent NHL was reviewed by PTAC, which recommended funding with a low priority, and noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS, uncertain evidence of an OS benefit, and no significant difference in safety or HRQoL. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the need for another agent in NHL and the potential impact of increasing infusion requirements due to maintenance therapy.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the applicant’s patient number estimate (N = 36) was reasonable and the estimate by PHARMAC staff (N = 9, based on bendamustine use in rituximab-refractory patients) was too low, but that bendamustine may be contraindicated in patients who are heavily pre-treated, of advanced age, or have co-morbidities. The Subcommittee considered that the small group of patients with relapsed/refractory indolent NHL have an unmet health need and that uptake of obinutuzumab plus bendamustine could be low due to patient characteristics. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab in combination with bendamustine for rituximab-refractory indolent NHL comes from the phase 3 GADOLIN trial; an open-label, randomised (1:1), multicentre trial that investigated the efficacy and safety of induction therapy with obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy, compared with bendamustine monotherapy induction therapy, in 413 patients with rituximab-refractory indolent NHL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27345636"" target=""_blank"">(Sehn et al. Lancet Oncol. 2016;17:1081-93; Cheson et al. J Clin Oncol. 2018;36:2259-66).</a> </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that limitations of the GADOLIN trial design and patient group characteristics would have biased the results; specifically, different doses of bendamustine (120 mg as monotherapy; 90 mg with obinutuzumab), use of bendamustine monotherapy as a comparator and without maintenance (patients more likely to progress than with obinutuzumab plus bendamustine), imbalances in the proportion of patients refractory to prior rituximab monotherapy (18.6% in the obinutuzumab plus bendamustine group and 23.0% in the monotherapy group in the intention-to-treat population, and in 15.2% and 24.6%, respectively, of patients with FL), and broad definitions of rituximab-refractory (applying to prior rituximab monotherapy and rituximab-containing combination chemotherapy regimens). The Subcommittee considered that rituximab monotherapy is seldom used in New Zealand, as patients may respond to rituximab with chemotherapy. </p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the UK National Institute for Health and Care Excellence (NICE) technology appraisal of obinutuzumab plus bendamustine had reported limitations in estimates of overall survival (OS) which favoured the intervention <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29594951"" target=""_blank"">(Rafia et al. Pharmacoeconomics. 2018;36:1143-51)</a>.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the median progression-free survival (PFS) in the GADOLIN trial was 25.8 months with obinutuzumab plus bendamustine compared to 14.1 months with bendamustine monotherapy (HR 0.57; 95% CI 0.44 to 0.73; P&lt;0.001). The Subcommittee noted that median OS was not reached for either group, where the Kaplan Meir survival differences were statistically significant (HR 0.67; 95% CI 0.47-0.96; P=0.0269) and considered that a reasonable number of survival events had occurred. The Subcommittee noted that the PFS and OS results were consistent in the FL patient subgroups <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29584548"" target=""_blank"">(Cheson et al. J Clin Oncol. 2018;36:2259-66)</a>.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that obinutuzumab had a reasonable safety profile, that adverse events (AEs) were similar between the treatment groups, and that the higher proportion of treatment withdrawals due to AEs with bendamustine monotherapy may be due to poor tolerance of the larger bendamustine dose in this group.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that GADOLIN demonstrated a PFS benefit and an apparent OS effect, despite the published data not being fully mature and the limitations of the trial. </p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the clinical trial evidence from the GADOLIN trial was highly relevant to New Zealand patients with indolent NHL, because the trial control arm used bendamustine monotherapy as would be the case in New Zealand for rituximab-refractory patients where a rituximab treatment-free interval of 12 months or more is required for renewal of rituximab on relapse. </p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the infusion resource required to administer obinutuzumab maintenance every 2 months for 2 years or until disease progression was small, that a small number of patients would receive this treatment, and that obinutuzumab maintenance would require similar infusion resources to maintenance rituximab (if funded), however, obinutuzumab may be more challenging to administer than rituximab. The Subcommittee considered that uptake of this regimen might be quite low. </p><p>Obinutuzumab for first-line treatment of FL</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for FL was reviewed by PTAC, which recommended the application be deferred pending further data, and that PTAC considered it should be funded only if cost-neutral to rituximab maintenance. The Subcommittee noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS but no evidence of quality of life benefit and no clear evidence of OS benefit with obinutuzumab compared with rituximab. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the long-term safety data of obinutuzumab and the likely efficacy of retreatment with obinutuzumab or rituximab.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the patient number estimates by the applicant (N = 119) and PHARMAC staff (N = 88) were reasonable estimates of the number of newly diagnosed patients with FL, although they could be slightly overestimated.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab induction and maintenance therapy for the first-line treatment of FL derives from the GALLIUM trial; an open-label, phase 3, randomised (1:1) trial that investigated the efficacy and safety of obinutuzumab plus chemotherapy induction therapy compared with rituximab plus chemotherapy followed by maintenance with the same antibody in 1202 patients with previously untreated FL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28976863"" target=""_blank"">(Marcus et al. N Engl J Med. 2017;377:1331-44</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the GALLIUM trial was of good quality, where it included patients with up to grade 3a disease, used the GELF tumour burden criteria for treatment eligibility, had a standard rituximab treatment schedule, and had a good balance of patients between treatment groups. The Subcommittee noted that three chemotherapy regimens were allowed: bendamustine (used in 57.1% of patients), CHOP (33.1%) and CVP (9.8%).</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that after a median follow-up of 41 months, the 3-year investigator-assessed PFS rate in the GALLIUM trial was 82% in the obinutuzumab group compared with 75% in the rituximab group (HR 0.68; 95% CI 0.54 to 0.87; P=0.0016), and that results of PFS as assessed by independent review committee were similar. Members considered that the PFS results by chemotherapy regimen were consistent. The Subcommittee noted that the 3-year OS rate was 94% in the obinutuzumab group compared with 92% in the rituximab group (HR 0.82; 95% CI 0.54 to 1.22; P=0.32) <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">(Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that secondary malignancy occurred in 5% of patients receiving bendamustine, more infections were reported in patients receiving bendamustine (20-26%) than other regimens (12-20%), and higher rates of grade 3-5 cytopenias were reported in patients receiving CHOP than with other regimens. The Subcommittee considered these safety signals were small, but that longer-term data is needed to evaluate their clinical significance. </p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in patients older than 70 years that a higher proportion of fatal events occurred prior to starting new anticancer therapy with bendamustine (13%) compared with CHOP (2%) or CVP (4%), and considered this was a concern due to patients likely being older at the time of their diagnosis with FL.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the difference in PFS between groups was small and that the GALLIUM trial data was too immature to conclude whether obinutuzumab would be preferred over rituximab for induction and maintenance treatment for FL. The Subcommittee requested that it see mature efficacy and safety data, once available, although it considered these data unlikely to be available for at least a few years. The Subcommittee considered that OS data was unlikely to be produced as it is challenging to obtain this in FL, due to confounding from crossovers with subsequent multiple lines of therapy.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there is no available data for retreatment using either obinutuzumab or rituximab after obinutuzumab in the first-line setting, and considered that the efficacy and safety of retreatment with obinutuzumab or rituximab is currently unknown. The Subcommittee considered that long-term safety and efficacy data are lacking in FL and there is a small signal for increased infections and secondary malignancy that requires additional follow up to determine if this is a concern.</p>', 'PTAC_Comments__c': '<p>PTAC <span style=""font-family: Arial, sans-serif; font-size: 10pt;"">noted and agreed with the Subcommittee’s recorded considerations and recommendations regarding the record. </span></p>', 'Status_History__c': 'a132P000000BUmKQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2021', 'fs': 'Aug 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvd2AB'}, 'Id': 'a0POZ00000B4bvd2AB', 'Event_Date__c': '2021-08-02', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2021', 'Status_History__c': 'a132P000000DaOcQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2021', 'fs': 'Sep 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Thursday 4 November 2021', 'fs': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Thursday 4 November 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bve2AB'}, 'Id': 'a0POZ00000B4bve2AB', 'Event_Date__c': '2021-09-01', 'Event_Description__c': 'Assigned to Cancer Treatments Advisory Committee meeting to provide advice on Thursday 4 November 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2021', 'Status_History__c': 'a132P000000DaRLQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>8.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab for the treatment of follicular lymphoma be listed if <b>cost neutral</b> to rituximab within the context treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – (follicular lymphoma)</b><span style=""font-size: 9pt;""> only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has indolent follicular lymphoma stage III or IV, or stage II bulky disease; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance status of 0-2; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 or more; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">4.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum dose of 1000 mg; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">4.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered for a maximum of 8 cycles in combination with CHOP, CVP, or bendamustine; </span></p><p><b style=""font-size: 9pt;"">\xa0</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal – (follicular lymphoma)</b><span style=""font-size: 9pt;""> only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has achieved a complete or partial response at the end of obinutuzumab induction therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be discontinued at disease progression.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Note: Response to first-line induction treatment in combination with obinutuzumab needs to be assessed 2-4 weeks after the last treatment course. Maintenance therapy should commence at 8 weeks after completion of induction treatment</span></p><p class=""ql-indent-1""><br></p><p>8.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee noted:</p><p class=""ql-indent-1"">8.3.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The small reduction in the proportion of patients progressing before 24 months when treated with obinutuzumab compared to rituximab.</p><p class=""ql-indent-1"">8.3.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The small improvements in progression free survival and time to next anti-lymphoma treatment for patients treated with obinutuzumab compared to those treated with rituximab.</p><p class=""ql-indent-1"">8.3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of overall survival or quality of life benefit for patients treated with obinutuzumab compared to rituximab</p>', 'fs': '<p>8.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab for the treatment of follicular lymphoma be listed if <b>cost neutral</b> to rituximab within the context treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – (follicular lymphoma)</b><span style=""font-size: 9pt;""> only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has indolent follicular lymphoma stage III or IV, or stage II bulky disease; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance status of 0-2; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 or more; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">4.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum dose of 1000 mg; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">4.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered for a maximum of 8 cycles in combination with CHOP, CVP, or bendamustine; </span></p><p><b style=""font-size: 9pt;"">\xa0</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal – (follicular lymphoma)</b><span style=""font-size: 9pt;""> only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has achieved a complete or partial response at the end of obinutuzumab induction therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be discontinued at disease progression.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Note: Response to first-line induction treatment in combination with obinutuzumab needs to be assessed 2-4 weeks after the last treatment course. Maintenance therapy should commence at 8 weeks after completion of induction treatment</span></p><p class=""ql-indent-1""><br></p><p>8.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee noted:</p><p class=""ql-indent-1"">8.3.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The small reduction in the proportion of patients progressing before 24 months when treated with obinutuzumab compared to rituximab.</p><p class=""ql-indent-1"">8.3.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The small improvements in progression free survival and time to next anti-lymphoma treatment for patients treated with obinutuzumab compared to those treated with rituximab.</p><p class=""ql-indent-1"">8.3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of overall survival or quality of life benefit for patients treated with obinutuzumab compared to rituximab</p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""font-size: 12px; color: windowtext;"">8.4</span><span style=""font-size: 12px; color: windowtext;"">\xa0\xa0</span><span style=""font-size: 7pt; color: windowtext;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that this application was first assessed by PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a>, and that the Committee recommended that obinutuzumab for use in combination with chemotherapy for the first-line induction and maintenance treatment of follicular lymphoma be deferred until additional data is made available regarding the long-term safety of obinutuzumab and the likely efficacy of obinutuzumab retreatment or rituximab containing regimens at relapse following first-line obinutuzumab. The Committee considered that the preferred option would be to fund rituximab maintenance initially, with obinutuzumab maintenance funded only if cost-neutral to rituximab maintenance. </p><p><span style=""color: windowtext;"">8.5</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PTAC requested advice from CaTSoP regarding long-term safety data for obinutuzumab, and the likely efficacy of treatment with obinutuzumab or rituximab. The Subcommittee noted that CaTSoP reviewed this application in <a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf"" target=""_blank"">October 2019</a>, and it recommended that funding be deferred pending more mature progression free survival (PFS) and safety data for this patient group from the GALLIUM trial, however considered that overall survival (OS) data was unlikely to be forthcoming in this patient group.</p><p>8.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in response to the above recommendations, the supplier has provided further follow-up data from the GALLIUM trial.</p><p>8.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that follicular lymphoma makes up approximately 30% of non-Hodgkin’s lymphoma (NHL), equating to approximately 250 patients annually in New Zealand. The Subcommittee noted that the majority of patients are over the age of 45 and considered that the incidence of NHL is consistent across ethnicities and socioeconomic groups. The Subcommittee noted that more than 80% of patients have stage 3 or 4 advanced disease at diagnosis, and that treatment for those with advanced disease is not curative in intent. The Subcommittee noted that localised disease at diagnosis that could be treated surgically, and potentially cured, is rare. The Subcommittee noted that over two thirds of patients require treatment immediately after initial progression, and that the remaining patients are managed with a ‘watch and wait’ approach. The Subcommittee considered that if obinutuzumab were to be funded for this indication, that approximately 110 patients annually would access obinutuzumab. </p><p>8.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that follicular lymphoma is typically indolent in nature with a median survival in all risk groups of advanced disease of greater than 5 years. The Subcommittee also noted that patients typically have a low symptom burden at diagnosis, and that treatment initiation is based on severity of symptoms (such as bulkiness of disease, systemic symptoms such as weight loss, or bone marrow failure). The Subcommittee considered that the majority of patients will require treatment within 2 years of initial diagnosis. The Subcommittee noted that the majority of patients do not die from their disease, but rather morbidities related to old age and other competing factors.</p><p>8.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the current first-line treatment option for follicular lymphoma requiring systemic therapy is chemo-immunotherapy – cyclophosphamide, vincristine and prednisone (CVP), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), or bendamustine chemotherapy with rituximab immunotherapy. The Subcommittee noted that bendamustine was funded in New Zealand in 2018 and is an approved chemotherapy option for follicular lymphoma patients. The Subcommittee noted that, in 2019, access to rituximab was widened to enable patients to continue rituximab treatment for two years as maintenance therapy. </p><p>8.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that upon relapse, patients usually receive further first line therapy or an alternative immunochemotherapeutic regimen. Some patients would receive consolidation with high dose therapy and autologous haematopoietic stem cell transplant (HSCT) with very few patients receiving an allogenic HSCT. Other patients may receive palliative treatments for symptom control (eg. radiotherapy). The Subcommittee noted that relapse of patients with follicular lymphoma within 24 months of treatment, identifies a subset of treated patients as more likely to require further treatment with shorter periods of response and perhaps shorter survival. </p><p>8.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that both rituximab and obinutuzumab are recombinant monoclonal antibodies directed against CD20, but that the two agents recognise different epitopes and have slightly different mechanisms of action. The Subcommittee noted that rituximab has limited direct cytotoxicity, but primarily works through complement-dependent cytotoxicity (CDC) and improvement of natural killer cell and macrophage cytotoxicity through FcỿRIIIA binding. The Subcommittee noted that obinutuzumab has increased antibody dependent cell-mediated cytotoxicity (ADCC), with minimal or no CDC, and greatly increases FcỿRIIIA affinity. The Subcommittee however considered that that it was unclear if CDC played an important role in the efficacy of treatment of follicular lymphoma. </p><p>8.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the use of obinutuzumab for the treatment of patients with previously untreated follicular lymphoma comes from the phase III randomised GALLIUM study (<a href=""https://www.nejm.org/doi/10.1056/NEJMoa1614598?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov#article_supplementary_material"" target=""_blank"">Marcus R, et al. N Engl J Med. 2017;377:1331-1344</a>) comparing rituximab in combination with chemotherapy with obinutuzumab in combination with chemotherapy in this patient group. The Subcommittee noted that the chemotherapy used was either cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), cyclophosphamide, vincristine and prednisone (CVP) or bendamustine. Patients were treated with rituximab or obinutuzumab with chemotherapy for 6 months, and then rituximab or obinutuzumab alone every two months as maintenance. The Subcommittee considered that the chemotherapy received by patients in this study and the relative proportions was reflective of the New Zealand patient population.</p><p>8.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a health related quality of life study from the GALLIUM trial with a median follow-up of 57.4 months which showed that the minimally clinically important difference (MCID) was not reached in either treatment group for physical wellbeing, emotional wellbeing, social wellbeing and that treatment with rituximab with chemotherapy improved functional wellbeing over the minimally clinically important threshold at follow-up months 36 and 48, obinutuzumab with chemotherapy did not (<a href=""https://pubmed.ncbi.nlm.nih.gov/32314038/"" target=""_blank"">Davies et al. Ann Hematol. 2020;99:2837-46</a>)</p><p>8.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that updated 5-year follow-up evidence has been provided by the supplier in the form of a conference abstract (<a href=""https://library.ehaweb.org/eha/2020/eha25th/293659/william.townsend.sustained.clinical.benefit.of.obinutuzumab.plus.chemotherapy.html"" target=""_blank"">Townsend et al. 25th European Hematology Association (EHA) Congress virtual edition June 2020</a>). The Subcommittee noted that the 5-year progression free survival was 70.5% with obinutuzumab and chemotherapy (95% CI 66.4 to 74.1) and 63.2% with rituximab with chemotherapy (95% CI 59.0 to 67.1; HR 0.76; 95% CI 0.62 to 0.92; p=0.0043). The Subcommittee also noted that the 5-year time to next anti-lymphoma treatment was longer for patients who received obinutuzumab compared to those who received rituximab(79.7% versus 72.9%; HR 0.72; 95% CI 0.57 to 0.90; p=0.0039) and that this represented a 28% reduction in the relative risk of requiring another line of treatment within 5 years.</p><p>8.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary issue with treatment of follicular lymphoma is with disease progression, specifically progression of disease within 24 months (POD 24). The Subcommittee noted that these patients with disease progression receive more treatment, have poorer outcomes with their salvage treatment, and experience shorter survival.</p><p>8.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that for patients who progressed within 24 months, there was no difference between the obinutuzumab and rituximab treated groups at a median post-progression follow up of 22.6 months, that overall survival (OS) also did not differ between the two treatment groups (HR 0.87; 95% CI 0.62 to 1.22; p=0.41) (<a href=""https://pubmed.ncbi.nlm.nih.gov/30573503/"" target=""_blank"">Seymour et al. Haematologica. 2019;104:1202-8</a>). The Subcommittee noted that the incidence of early disease progression (ie within 24 months) was less in the obinutuzumab treated arm compared to the rituximab treated arm (9.2% versus 16.3%, respectively) and the average hazard ratio based reduction in risk of progressing before 24 months with obinutuzumab relative to rituximab was 47.6% (95% CI 27.1 to 62.4). The Subcommittee considered that the evidence for the use of obinutuzumab in the treatment of follicular lymphoma was of good strength and good quality. </p><p>8.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that improved progression-free survival (PFS) was observed for obinutuzumab in combination with chemotherapy, regardless of the backbone chemotherapy received. The Subcommittee noted that, while the different chemotherapy regimens have differing safety profiles, the results of the GALLIUM trial are confounded by the non-random chemotherapy allocation of each patient and that this precludes comparisons between chemotherapy agents. The Subcommittee also considered that the relative proportions of patients undergoing different chemotherapy treatments from the GALLIUM trial were likely applicable to the New Zealand patient population. </p><p>8.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the results from the GALLIUM trial indicate that the first dose with obinutuzumab is commonly associated with grade III to V adverse reactions and these were related to infusion reactions. The Subcommittee also noted that obinutuzumab must be administered over 6 hours in a hospital setting for the first dose and 3–4-hour infusions for subsequent doses, while rituximab can be administered in an outpatient setting. </p><p>8.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients receiving treatment with rituximab receive a body-surface-area adjusted dose with each cycle of chemotherapy, plus a single dose of rituximab monotherapy every 8 weeks for two years. The Subcommittee also noted that patients receiving treatment with obinutuzumab received larger fixed doses and also received extra doses in the first cycle (3 doses in the first month), but that subsequent dosing frequency was the same as rituximab. </p><p>8.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted results from the GAZELLE study, presented at ASCO 2021, which demonstrated that patients could receive 90 minute infusions from the second cycle onwards, without an increase in grade III to V adverse events <a href=""https://onlinelibrary.wiley.com/doi/10.1002/hon.30_2880"" target=""_blank"">(Hubel et al. International Conference on Malignant Lymphoma. 2021;39:Supplement</a>). The Subcommittee considered that this would translate to a benefit for patients and infusion services. </p><p>8.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the response rates, survival outcomes and treatment complications are similar between rituximab and obinutuzumab, but that obinutuzumab treatment decreases the proportion of patients with POD24. The Subcommittee considered that the most benefit would be seen in the small group of patients that experienced POD24 while receiving rituximab that may have otherwise not if they had received obinutuzumab. The Subcommittee considered that on balance, the benefit of obinutuzumab in this patient population would be difficult to model due to the lack of overall survival benefit, uncertain long-term benefit and lack of improvements in quality of life for obinutuzumab compared to rituximab. </p><p>8.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that funding obinutuzumab for this indication would not materially impact health-sector expenditure as while time to next treatment is delayed, there is no demonstrable increased survival for patients after 5 years. </p><p>8.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Subcommittee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for obinutuzumab if it were to be funded in New Zealand for the </span>treatment<span style=""color: black;""> of follicular lymphoma. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000B4bvf&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001vmEs"" alt=""image.png""></img></p>', 'fs': '<p><span style=""font-size: 12px; color: windowtext;"">8.4</span><span style=""font-size: 12px; color: windowtext;"">\xa0\xa0</span><span style=""font-size: 7pt; color: windowtext;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that this application was first assessed by PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a>, and that the Committee recommended that obinutuzumab for use in combination with chemotherapy for the first-line induction and maintenance treatment of follicular lymphoma be deferred until additional data is made available regarding the long-term safety of obinutuzumab and the likely efficacy of obinutuzumab retreatment or rituximab containing regimens at relapse following first-line obinutuzumab. The Committee considered that the preferred option would be to fund rituximab maintenance initially, with obinutuzumab maintenance funded only if cost-neutral to rituximab maintenance. </p><p><span style=""color: windowtext;"">8.5</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PTAC requested advice from CaTSoP regarding long-term safety data for obinutuzumab, and the likely efficacy of treatment with obinutuzumab or rituximab. The Subcommittee noted that CaTSoP reviewed this application in <a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf"" target=""_blank"">October 2019</a>, and it recommended that funding be deferred pending more mature progression free survival (PFS) and safety data for this patient group from the GALLIUM trial, however considered that overall survival (OS) data was unlikely to be forthcoming in this patient group.</p><p>8.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in response to the above recommendations, the supplier has provided further follow-up data from the GALLIUM trial.</p><p>8.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that follicular lymphoma makes up approximately 30% of non-Hodgkin’s lymphoma (NHL), equating to approximately 250 patients annually in New Zealand. The Subcommittee noted that the majority of patients are over the age of 45 and considered that the incidence of NHL is consistent across ethnicities and socioeconomic groups. The Subcommittee noted that more than 80% of patients have stage 3 or 4 advanced disease at diagnosis, and that treatment for those with advanced disease is not curative in intent. The Subcommittee noted that localised disease at diagnosis that could be treated surgically, and potentially cured, is rare. The Subcommittee noted that over two thirds of patients require treatment immediately after initial progression, and that the remaining patients are managed with a ‘watch and wait’ approach. The Subcommittee considered that if obinutuzumab were to be funded for this indication, that approximately 110 patients annually would access obinutuzumab. </p><p>8.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that follicular lymphoma is typically indolent in nature with a median survival in all risk groups of advanced disease of greater than 5 years. The Subcommittee also noted that patients typically have a low symptom burden at diagnosis, and that treatment initiation is based on severity of symptoms (such as bulkiness of disease, systemic symptoms such as weight loss, or bone marrow failure). The Subcommittee considered that the majority of patients will require treatment within 2 years of initial diagnosis. The Subcommittee noted that the majority of patients do not die from their disease, but rather morbidities related to old age and other competing factors.</p><p>8.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the current first-line treatment option for follicular lymphoma requiring systemic therapy is chemo-immunotherapy – cyclophosphamide, vincristine and prednisone (CVP), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), or bendamustine chemotherapy with rituximab immunotherapy. The Subcommittee noted that bendamustine was funded in New Zealand in 2018 and is an approved chemotherapy option for follicular lymphoma patients. The Subcommittee noted that, in 2019, access to rituximab was widened to enable patients to continue rituximab treatment for two years as maintenance therapy. </p><p>8.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that upon relapse, patients usually receive further first line therapy or an alternative immunochemotherapeutic regimen. Some patients would receive consolidation with high dose therapy and autologous haematopoietic stem cell transplant (HSCT) with very few patients receiving an allogenic HSCT. Other patients may receive palliative treatments for symptom control (eg. radiotherapy). The Subcommittee noted that relapse of patients with follicular lymphoma within 24 months of treatment, identifies a subset of treated patients as more likely to require further treatment with shorter periods of response and perhaps shorter survival. </p><p>8.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that both rituximab and obinutuzumab are recombinant monoclonal antibodies directed against CD20, but that the two agents recognise different epitopes and have slightly different mechanisms of action. The Subcommittee noted that rituximab has limited direct cytotoxicity, but primarily works through complement-dependent cytotoxicity (CDC) and improvement of natural killer cell and macrophage cytotoxicity through FcỿRIIIA binding. The Subcommittee noted that obinutuzumab has increased antibody dependent cell-mediated cytotoxicity (ADCC), with minimal or no CDC, and greatly increases FcỿRIIIA affinity. The Subcommittee however considered that that it was unclear if CDC played an important role in the efficacy of treatment of follicular lymphoma. </p><p>8.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the use of obinutuzumab for the treatment of patients with previously untreated follicular lymphoma comes from the phase III randomised GALLIUM study (<a href=""https://www.nejm.org/doi/10.1056/NEJMoa1614598?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov#article_supplementary_material"" target=""_blank"">Marcus R, et al. N Engl J Med. 2017;377:1331-1344</a>) comparing rituximab in combination with chemotherapy with obinutuzumab in combination with chemotherapy in this patient group. The Subcommittee noted that the chemotherapy used was either cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), cyclophosphamide, vincristine and prednisone (CVP) or bendamustine. Patients were treated with rituximab or obinutuzumab with chemotherapy for 6 months, and then rituximab or obinutuzumab alone every two months as maintenance. The Subcommittee considered that the chemotherapy received by patients in this study and the relative proportions was reflective of the New Zealand patient population.</p><p>8.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a health related quality of life study from the GALLIUM trial with a median follow-up of 57.4 months which showed that the minimally clinically important difference (MCID) was not reached in either treatment group for physical wellbeing, emotional wellbeing, social wellbeing and that treatment with rituximab with chemotherapy improved functional wellbeing over the minimally clinically important threshold at follow-up months 36 and 48, obinutuzumab with chemotherapy did not (<a href=""https://pubmed.ncbi.nlm.nih.gov/32314038/"" target=""_blank"">Davies et al. Ann Hematol. 2020;99:2837-46</a>)</p><p>8.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that updated 5-year follow-up evidence has been provided by the supplier in the form of a conference abstract (<a href=""https://library.ehaweb.org/eha/2020/eha25th/293659/william.townsend.sustained.clinical.benefit.of.obinutuzumab.plus.chemotherapy.html"" target=""_blank"">Townsend et al. 25th European Hematology Association (EHA) Congress virtual edition June 2020</a>). The Subcommittee noted that the 5-year progression free survival was 70.5% with obinutuzumab and chemotherapy (95% CI 66.4 to 74.1) and 63.2% with rituximab with chemotherapy (95% CI 59.0 to 67.1; HR 0.76; 95% CI 0.62 to 0.92; p=0.0043). The Subcommittee also noted that the 5-year time to next anti-lymphoma treatment was longer for patients who received obinutuzumab compared to those who received rituximab(79.7% versus 72.9%; HR 0.72; 95% CI 0.57 to 0.90; p=0.0039) and that this represented a 28% reduction in the relative risk of requiring another line of treatment within 5 years.</p><p>8.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary issue with treatment of follicular lymphoma is with disease progression, specifically progression of disease within 24 months (POD 24). The Subcommittee noted that these patients with disease progression receive more treatment, have poorer outcomes with their salvage treatment, and experience shorter survival.</p><p>8.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that for patients who progressed within 24 months, there was no difference between the obinutuzumab and rituximab treated groups at a median post-progression follow up of 22.6 months, that overall survival (OS) also did not differ between the two treatment groups (HR 0.87; 95% CI 0.62 to 1.22; p=0.41) (<a href=""https://pubmed.ncbi.nlm.nih.gov/30573503/"" target=""_blank"">Seymour et al. Haematologica. 2019;104:1202-8</a>). The Subcommittee noted that the incidence of early disease progression (ie within 24 months) was less in the obinutuzumab treated arm compared to the rituximab treated arm (9.2% versus 16.3%, respectively) and the average hazard ratio based reduction in risk of progressing before 24 months with obinutuzumab relative to rituximab was 47.6% (95% CI 27.1 to 62.4). The Subcommittee considered that the evidence for the use of obinutuzumab in the treatment of follicular lymphoma was of good strength and good quality. </p><p>8.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that improved progression-free survival (PFS) was observed for obinutuzumab in combination with chemotherapy, regardless of the backbone chemotherapy received. The Subcommittee noted that, while the different chemotherapy regimens have differing safety profiles, the results of the GALLIUM trial are confounded by the non-random chemotherapy allocation of each patient and that this precludes comparisons between chemotherapy agents. The Subcommittee also considered that the relative proportions of patients undergoing different chemotherapy treatments from the GALLIUM trial were likely applicable to the New Zealand patient population. </p><p>8.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the results from the GALLIUM trial indicate that the first dose with obinutuzumab is commonly associated with grade III to V adverse reactions and these were related to infusion reactions. The Subcommittee also noted that obinutuzumab must be administered over 6 hours in a hospital setting for the first dose and 3–4-hour infusions for subsequent doses, while rituximab can be administered in an outpatient setting. </p><p>8.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients receiving treatment with rituximab receive a body-surface-area adjusted dose with each cycle of chemotherapy, plus a single dose of rituximab monotherapy every 8 weeks for two years. The Subcommittee also noted that patients receiving treatment with obinutuzumab received larger fixed doses and also received extra doses in the first cycle (3 doses in the first month), but that subsequent dosing frequency was the same as rituximab. </p><p>8.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted results from the GAZELLE study, presented at ASCO 2021, which demonstrated that patients could receive 90 minute infusions from the second cycle onwards, without an increase in grade III to V adverse events <a href=""https://onlinelibrary.wiley.com/doi/10.1002/hon.30_2880"" target=""_blank"">(Hubel et al. International Conference on Malignant Lymphoma. 2021;39:Supplement</a>). The Subcommittee considered that this would translate to a benefit for patients and infusion services. </p><p>8.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the response rates, survival outcomes and treatment complications are similar between rituximab and obinutuzumab, but that obinutuzumab treatment decreases the proportion of patients with POD24. The Subcommittee considered that the most benefit would be seen in the small group of patients that experienced POD24 while receiving rituximab that may have otherwise not if they had received obinutuzumab. The Subcommittee considered that on balance, the benefit of obinutuzumab in this patient population would be difficult to model due to the lack of overall survival benefit, uncertain long-term benefit and lack of improvements in quality of life for obinutuzumab compared to rituximab. </p><p>8.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that funding obinutuzumab for this indication would not materially impact health-sector expenditure as while time to next treatment is delayed, there is no demonstrable increased survival for patients after 5 years. </p><p>8.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Subcommittee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for obinutuzumab if it were to be funded in New Zealand for the </span>treatment<span style=""color: black;""> of follicular lymphoma. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000B4bvf&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001vmEs"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: rgb(68, 68, 68);"">8.1</span><span style=""color: rgb(68, 68, 68); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: rgb(68, 68, 68);"">The Subcommittee considered an application from Roche Products (New Zealand) Ltd for the use of obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL).</span></p>', 'fs': '<p><span style=""color: rgb(68, 68, 68);"">8.1</span><span style=""color: rgb(68, 68, 68); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: rgb(68, 68, 68);"">The Subcommittee considered an application from Roche Products (New Zealand) Ltd for the use of obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL).</span></p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Cost Neutral', 'fs': 'Cost Neutral', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Thursday 4 November 2021.', 'fs': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Thursday 4 November 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvf2AB'}, 'Id': 'a0POZ00000B4bvf2AB', 'Event_Date__c': '2022-03-11', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Advisory Committee at meeting Thursday 4 November 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Cost Neutral', 'Formatted_Date__c': 'Mar 2022', 'Published_Recommendation__c': '<p>8.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab for the treatment of follicular lymphoma be listed if <b>cost neutral</b> to rituximab within the context treatment of malignancy, subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – (follicular lymphoma)</b><span style=""font-size: 9pt;""> only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has indolent follicular lymphoma stage III or IV, or stage II bulky disease; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance status of 0-2; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 or more; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">4.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum dose of 1000 mg; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">4.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered for a maximum of 8 cycles in combination with CHOP, CVP, or bendamustine; </span></p><p><b style=""font-size: 9pt;"">\xa0</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal – (follicular lymphoma)</b><span style=""font-size: 9pt;""> only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has achieved a complete or partial response at the end of obinutuzumab induction therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be discontinued at disease progression.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Note: Response to first-line induction treatment in combination with obinutuzumab needs to be assessed 2-4 weeks after the last treatment course. Maintenance therapy should commence at 8 weeks after completion of induction treatment</span></p><p class=""ql-indent-1""><br></p><p>8.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee noted:</p><p class=""ql-indent-1"">8.3.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The small reduction in the proportion of patients progressing before 24 months when treated with obinutuzumab compared to rituximab.</p><p class=""ql-indent-1"">8.3.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The small improvements in progression free survival and time to next anti-lymphoma treatment for patients treated with obinutuzumab compared to those treated with rituximab.</p><p class=""ql-indent-1"">8.3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of overall survival or quality of life benefit for patients treated with obinutuzumab compared to rituximab</p>', 'Published_Application__c': '<p><span style=""color: rgb(68, 68, 68);"">8.1</span><span style=""color: rgb(68, 68, 68); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: rgb(68, 68, 68);"">The Subcommittee considered an application from Roche Products (New Zealand) Ltd for the use of obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL).</span></p>', 'Published_Discussion__c': '<p><span style=""font-size: 12px; color: windowtext;"">8.4</span><span style=""font-size: 12px; color: windowtext;"">\xa0\xa0</span><span style=""font-size: 7pt; color: windowtext;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that this application was first assessed by PTAC in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a>, and that the Committee recommended that obinutuzumab for use in combination with chemotherapy for the first-line induction and maintenance treatment of follicular lymphoma be deferred until additional data is made available regarding the long-term safety of obinutuzumab and the likely efficacy of obinutuzumab retreatment or rituximab containing regimens at relapse following first-line obinutuzumab. The Committee considered that the preferred option would be to fund rituximab maintenance initially, with obinutuzumab maintenance funded only if cost-neutral to rituximab maintenance. </p><p><span style=""color: windowtext;"">8.5</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PTAC requested advice from CaTSoP regarding long-term safety data for obinutuzumab, and the likely efficacy of treatment with obinutuzumab or rituximab. The Subcommittee noted that CaTSoP reviewed this application in <a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf"" target=""_blank"">October 2019</a>, and it recommended that funding be deferred pending more mature progression free survival (PFS) and safety data for this patient group from the GALLIUM trial, however considered that overall survival (OS) data was unlikely to be forthcoming in this patient group.</p><p>8.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in response to the above recommendations, the supplier has provided further follow-up data from the GALLIUM trial.</p><p>8.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that follicular lymphoma makes up approximately 30% of non-Hodgkin’s lymphoma (NHL), equating to approximately 250 patients annually in New Zealand. The Subcommittee noted that the majority of patients are over the age of 45 and considered that the incidence of NHL is consistent across ethnicities and socioeconomic groups. The Subcommittee noted that more than 80% of patients have stage 3 or 4 advanced disease at diagnosis, and that treatment for those with advanced disease is not curative in intent. The Subcommittee noted that localised disease at diagnosis that could be treated surgically, and potentially cured, is rare. The Subcommittee noted that over two thirds of patients require treatment immediately after initial progression, and that the remaining patients are managed with a ‘watch and wait’ approach. The Subcommittee considered that if obinutuzumab were to be funded for this indication, that approximately 110 patients annually would access obinutuzumab. </p><p>8.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that follicular lymphoma is typically indolent in nature with a median survival in all risk groups of advanced disease of greater than 5 years. The Subcommittee also noted that patients typically have a low symptom burden at diagnosis, and that treatment initiation is based on severity of symptoms (such as bulkiness of disease, systemic symptoms such as weight loss, or bone marrow failure). The Subcommittee considered that the majority of patients will require treatment within 2 years of initial diagnosis. The Subcommittee noted that the majority of patients do not die from their disease, but rather morbidities related to old age and other competing factors.</p><p>8.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the current first-line treatment option for follicular lymphoma requiring systemic therapy is chemo-immunotherapy – cyclophosphamide, vincristine and prednisone (CVP), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), or bendamustine chemotherapy with rituximab immunotherapy. The Subcommittee noted that bendamustine was funded in New Zealand in 2018 and is an approved chemotherapy option for follicular lymphoma patients. The Subcommittee noted that, in 2019, access to rituximab was widened to enable patients to continue rituximab treatment for two years as maintenance therapy. </p><p>8.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that upon relapse, patients usually receive further first line therapy or an alternative immunochemotherapeutic regimen. Some patients would receive consolidation with high dose therapy and autologous haematopoietic stem cell transplant (HSCT) with very few patients receiving an allogenic HSCT. Other patients may receive palliative treatments for symptom control (eg. radiotherapy). The Subcommittee noted that relapse of patients with follicular lymphoma within 24 months of treatment, identifies a subset of treated patients as more likely to require further treatment with shorter periods of response and perhaps shorter survival. </p><p>8.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that both rituximab and obinutuzumab are recombinant monoclonal antibodies directed against CD20, but that the two agents recognise different epitopes and have slightly different mechanisms of action. The Subcommittee noted that rituximab has limited direct cytotoxicity, but primarily works through complement-dependent cytotoxicity (CDC) and improvement of natural killer cell and macrophage cytotoxicity through FcỿRIIIA binding. The Subcommittee noted that obinutuzumab has increased antibody dependent cell-mediated cytotoxicity (ADCC), with minimal or no CDC, and greatly increases FcỿRIIIA affinity. The Subcommittee however considered that that it was unclear if CDC played an important role in the efficacy of treatment of follicular lymphoma. </p><p>8.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the use of obinutuzumab for the treatment of patients with previously untreated follicular lymphoma comes from the phase III randomised GALLIUM study (<a href=""https://www.nejm.org/doi/10.1056/NEJMoa1614598?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov#article_supplementary_material"" target=""_blank"">Marcus R, et al. N Engl J Med. 2017;377:1331-1344</a>) comparing rituximab in combination with chemotherapy with obinutuzumab in combination with chemotherapy in this patient group. The Subcommittee noted that the chemotherapy used was either cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), cyclophosphamide, vincristine and prednisone (CVP) or bendamustine. Patients were treated with rituximab or obinutuzumab with chemotherapy for 6 months, and then rituximab or obinutuzumab alone every two months as maintenance. The Subcommittee considered that the chemotherapy received by patients in this study and the relative proportions was reflective of the New Zealand patient population.</p><p>8.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a health related quality of life study from the GALLIUM trial with a median follow-up of 57.4 months which showed that the minimally clinically important difference (MCID) was not reached in either treatment group for physical wellbeing, emotional wellbeing, social wellbeing and that treatment with rituximab with chemotherapy improved functional wellbeing over the minimally clinically important threshold at follow-up months 36 and 48, obinutuzumab with chemotherapy did not (<a href=""https://pubmed.ncbi.nlm.nih.gov/32314038/"" target=""_blank"">Davies et al. Ann Hematol. 2020;99:2837-46</a>)</p><p>8.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that updated 5-year follow-up evidence has been provided by the supplier in the form of a conference abstract (<a href=""https://library.ehaweb.org/eha/2020/eha25th/293659/william.townsend.sustained.clinical.benefit.of.obinutuzumab.plus.chemotherapy.html"" target=""_blank"">Townsend et al. 25th European Hematology Association (EHA) Congress virtual edition June 2020</a>). The Subcommittee noted that the 5-year progression free survival was 70.5% with obinutuzumab and chemotherapy (95% CI 66.4 to 74.1) and 63.2% with rituximab with chemotherapy (95% CI 59.0 to 67.1; HR 0.76; 95% CI 0.62 to 0.92; p=0.0043). The Subcommittee also noted that the 5-year time to next anti-lymphoma treatment was longer for patients who received obinutuzumab compared to those who received rituximab(79.7% versus 72.9%; HR 0.72; 95% CI 0.57 to 0.90; p=0.0039) and that this represented a 28% reduction in the relative risk of requiring another line of treatment within 5 years.</p><p>8.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary issue with treatment of follicular lymphoma is with disease progression, specifically progression of disease within 24 months (POD 24). The Subcommittee noted that these patients with disease progression receive more treatment, have poorer outcomes with their salvage treatment, and experience shorter survival.</p><p>8.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that for patients who progressed within 24 months, there was no difference between the obinutuzumab and rituximab treated groups at a median post-progression follow up of 22.6 months, that overall survival (OS) also did not differ between the two treatment groups (HR 0.87; 95% CI 0.62 to 1.22; p=0.41) (<a href=""https://pubmed.ncbi.nlm.nih.gov/30573503/"" target=""_blank"">Seymour et al. Haematologica. 2019;104:1202-8</a>). The Subcommittee noted that the incidence of early disease progression (ie within 24 months) was less in the obinutuzumab treated arm compared to the rituximab treated arm (9.2% versus 16.3%, respectively) and the average hazard ratio based reduction in risk of progressing before 24 months with obinutuzumab relative to rituximab was 47.6% (95% CI 27.1 to 62.4). The Subcommittee considered that the evidence for the use of obinutuzumab in the treatment of follicular lymphoma was of good strength and good quality. </p><p>8.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that improved progression-free survival (PFS) was observed for obinutuzumab in combination with chemotherapy, regardless of the backbone chemotherapy received. The Subcommittee noted that, while the different chemotherapy regimens have differing safety profiles, the results of the GALLIUM trial are confounded by the non-random chemotherapy allocation of each patient and that this precludes comparisons between chemotherapy agents. The Subcommittee also considered that the relative proportions of patients undergoing different chemotherapy treatments from the GALLIUM trial were likely applicable to the New Zealand patient population. </p><p>8.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the results from the GALLIUM trial indicate that the first dose with obinutuzumab is commonly associated with grade III to V adverse reactions and these were related to infusion reactions. The Subcommittee also noted that obinutuzumab must be administered over 6 hours in a hospital setting for the first dose and 3–4-hour infusions for subsequent doses, while rituximab can be administered in an outpatient setting. </p><p>8.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients receiving treatment with rituximab receive a body-surface-area adjusted dose with each cycle of chemotherapy, plus a single dose of rituximab monotherapy every 8 weeks for two years. The Subcommittee also noted that patients receiving treatment with obinutuzumab received larger fixed doses and also received extra doses in the first cycle (3 doses in the first month), but that subsequent dosing frequency was the same as rituximab. </p><p>8.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted results from the GAZELLE study, presented at ASCO 2021, which demonstrated that patients could receive 90 minute infusions from the second cycle onwards, without an increase in grade III to V adverse events <a href=""https://onlinelibrary.wiley.com/doi/10.1002/hon.30_2880"" target=""_blank"">(Hubel et al. International Conference on Malignant Lymphoma. 2021;39:Supplement</a>). The Subcommittee considered that this would translate to a benefit for patients and infusion services. </p><p>8.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the response rates, survival outcomes and treatment complications are similar between rituximab and obinutuzumab, but that obinutuzumab treatment decreases the proportion of patients with POD24. The Subcommittee considered that the most benefit would be seen in the small group of patients that experienced POD24 while receiving rituximab that may have otherwise not if they had received obinutuzumab. The Subcommittee considered that on balance, the benefit of obinutuzumab in this patient population would be difficult to model due to the lack of overall survival benefit, uncertain long-term benefit and lack of improvements in quality of life for obinutuzumab compared to rituximab. </p><p>8.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that funding obinutuzumab for this indication would not materially impact health-sector expenditure as while time to next treatment is delayed, there is no demonstrable increased survival for patients after 5 years. </p><p>8.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""color: black;"">The Subcommittee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for obinutuzumab if it were to be funded in New Zealand for the </span>treatment<span style=""color: black;""> of follicular lymphoma. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Subcommittee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ00000B4bvf&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000001vmEs"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000DbnIQAS'}, 'change': None}]",Jun 2018,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvg2AB'}, 'Id': 'a0POZ00000B4bvg2AB', 'Event_Date__c': '2022-03-31', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000EDYkQAO'}, 'change': None}]",Mar 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2023', 'fs': 'Jun 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvh2AB'}, 'Id': 'a0POZ00000B4bvh2AB', 'Event_Date__c': '2023-06-12', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2023', 'Status_History__c': 'a132P000000EOPLQA4'}, 'change': None}]",Jun 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvi2AB'}, 'Id': 'a0POZ00000B4bvi2AB', 'Event_Date__c': '2023-12-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-12-proposal-to-decline-inactive-funding-applications-2"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004kgoLYAQ'}, 'change': None}]",Dec 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2024', 'fs': 'Feb 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvj2AB'}, 'Id': 'a0POZ00000B4bvj2AB', 'Event_Date__c': '2024-02-12', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Feb 2024', 'Status_History__c': 'a13OZ000006m0QZYAY'}, 'change': None}]",Feb 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2024', 'fs': 'Jul 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000B4bvk2AB'}, 'Id': 'a0POZ00000B4bvk2AB', 'Event_Date__c': '2024-07-29', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-decline-inactive-funding-applications-july-24"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Jul 2024', 'Status_History__c': 'a13OZ00000Cfj3zYAB'}, 'change': None}]",Jul 2024,False,True
